Biotech Innovation Target Neugenesis as a niche biotech innovator focused on heteromeric protein discovery and production. Align sales discussions around capabilities in directed evolution, combinatorial biology, and recombinant protein expression to address clients seeking advanced biotherapeutics development.

Post-Acquisition Opportunity Note that Neugenesis was acquired by Intrexon in 2011. Use this to position offerings as complementary to large biotech ecosystems and explore collaboration or integration opportunities with Intrexon’s broader portfolio.

Small Team, High Impact With a lean headcount (2–10 employees), emphasize scalable, cost-efficient solutions and rapid pilot programs. Propose modular services or technology licensing that fits a small, agile R&D setup while enabling path-to-scale.

Cloud and Tech Stacks Leverage their use of Google Cloud, Nginx/OpenResty, Lua, and Network Solutions to propose cloud-based collaboration platforms, secure data sharing, and streamlined computational workflows that fit existing infrastructure.

Revenue Growth Pitch Revenue range indicates early-stage commercial traction. Position value propositions around accelerating time-to-market for complex proteins, cost reductions in production, and potential for joint product development with larger systems integrators or CROs to expand revenue channels.